We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+27.19%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$497M
AUM Growth
+$112M
Cap. Flow
+$51.3M
Cap. Flow %
10.33%
Top 10 Hldgs %
64.94%
Holding
41
New
10
Increased
17
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$20.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$11.4M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$10.1M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$7.94M
5
KALV
KalVista Pharmaceuticals
KALV
+$7.02M

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$28.3M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$22.5M
3
QURE icon
uniQure
QURE
+$7.01M
4
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$5.06M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$82.3M 16.57%
7,648,268
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$47.8M 9.62%
1,214,662
+168,971
+16% +$5.96M
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$38.6M 7.76%
1,003,406
+805,600
+407% +$20.7M
GERN icon
4
Geron
GERN
$970M
$29.5M 5.94%
9,191,290
+789,725
+9% +$2.25M
RETA
5
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$23.9M 4.81%
234,478
+57,604
+33% +$5.45M
ITOS
6
DELISTED
iTeos Therapeutics
ITOS
$23.1M 4.65%
1,745,943
– –
NTLA icon
7
Intellia Therapeutics
NTLA
$1.8B
$22.2M 4.47%
544,639
-27,820
-5% -$1.13M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$3.63B
$20.8M 4.18%
2,950,118
+335,141
+13% +$2.4M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$17.3M 3.49%
1,639,849
– –
RLAY icon
10
Relay Therapeutics
RLAY
$4.11B
$17M 3.43%
1,354,368
+128,734
+11% +$1.6M
VERV
11
DELISTED
Verve Therapeutics
VERV
$16.1M 3.24%
857,940
+54,439
+7% +$907K
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.28B
$15.1M 3.03%
+295,111
New +$7.94M
RGNX icon
13
Regenxbio
RGNX
$638M
$13.1M 2.64%
656,718
+39,047
+6% +$752K
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$11.6M 2.33%
+53,399
New +$11.4M
INSM icon
15
Insmed
INSM
$25.9B
$11.2M 2.25%
529,743
+130,551
+33% +$2.48M
XERS icon
16
Xeris Biopharma Holdings
XERS
$1.55B
$10.4M 2.1%
+3,974,999
New +$10.1M
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.3B
$8.78M 1.77%
38,011
+1,973
+5% +$534K
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$9B
$8.63M 1.74%
479,053
+118,661
+33% +$2.37M
TVTX icon
19
Travere Therapeutics
TVTX
$6.19B
$8.49M 1.71%
552,846
+239,204
+76% +$4.35M
RVMD icon
20
Revolution Medicines
RVMD
$44.6B
$7.31M 1.47%
273,408
+26,386
+11% +$647K
HOWL icon
21
Werewolf Therapeutics
HOWL
$45.8M
$7.28M 1.47%
2,388,011
– –
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$6.85M 1.38%
+761,538
New +$7.02M
AXSM icon
23
Axsome Therapeutics
AXSM
$10.4B
$6.73M 1.35%
93,586
+23,184
+33% +$1.71M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$6.48M 1.31%
516,139
+127,847
+33% +$1.52M
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
$6.34M 1.28%
+384,990
New +$5M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2023 Portfolio in Review

As of Q2 2023, MPM BioImpact held 41 positions worth $497M, up 29% from $385M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

MPM BioImpact deployed $51.3M of net new capital in Q2 2023, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Intellia Therapeutics, an estimated $1.13M trimmed.

  • MPM BioImpact's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.
  • MPM BioImpact added most to Chinook Therapeutics, Inc. Common Stock in Q2 2023, an estimated $20.7M increase.
  • MPM BioImpact's biggest Q2 2023 reduction was Intellia Therapeutics, cutting an estimated $1.13M.
  • MPM BioImpact fully exited Provention Bio, Inc. Common Stock in Q2 2023, selling an estimated $28.3M.
  • MPM BioImpact's ten largest holdings make up 65% of its $497M portfolio in Q2 2023.
  • MPM BioImpact opened 10 new positions and closed 7 in Q2 2023.
  • MPM BioImpact's portfolio value rose 29% quarter-over-quarter to $497M.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.